Aoki Daisuke, Watanabe Yoh, Jobo Toshiko, Ushijima Kimio, Hasegawa Kiyoshi, Susumu Nobuyuki, Suzuki Nao, Aoki Rui, Isonishi Seiji, Sagae Satoru, Ishizuka Bunpei, Kamura Toshiharu, Udagawa Yasuhiro, Hoshiai Hiroshi, Ohashi Yasuo, Ochiai Kazunori, Noda Kiichiro
Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo, 160-8582, Japan.
Anticancer Res. 2009 Feb;29(2):561-6.
The long-term efficacy and safety of docetaxel/cisplatin as first-line chemotherapy in Japanese patients was evaluated in order to find an optional regimen for ovarian cancer.
Women with surgically resected stage Ic-IV epithelial ovarian cancer were treated with docetaxel 70 mg/m2 and cisplatin 60 mg/m2 every 4 weeks.
Ninety women were enrolled of whom 89 (median age, 54 years) received a median of 6 cycles (range 1 to 9). With a median 38 months'follow-up, median progression-free survival was 28 months (95% lower confidence interval, 24 months) in 60 patients with stage III-IV disease. The overall response rate for 20 patients was 45%. Neutropenia was the most common (67%) grade 3/4 toxicity. Major grade 3/4 nonhaematological toxicities were gastrointestinal toxicities (< or = 11%) and fatigue (8%). No grade 3/4 neurotoxicity was observed.
The combination of docetaxel/cisplatin is a regimen with favourable progression-free survival for ovarian cancer.
为了找到一种适用于卵巢癌的最佳方案，对多西他赛/顺铂作为日本患者一线化疗方案的长期疗效和安全性进行了评估。
对经手术切除的Ⅰc - Ⅳ期上皮性卵巢癌女性患者，每4周给予多西他赛70mg/m²和顺铂60mg/m²进行治疗。
90名女性入组，其中89名（中位年龄54岁）接受了中位6个周期（范围1至9个周期）的治疗。在60例Ⅲ - Ⅳ期疾病患者中，中位随访38个月，中位无进展生存期为28个月（95%置信区间下限为24个月）。20例患者的总缓解率为45%。中性粒细胞减少是最常见的3/4级毒性反应（67%）。主要的3/4级非血液学毒性反应为胃肠道毒性反应（≤11%）和疲劳（8%）。未观察到3/4级神经毒性反应。
多西他赛/顺铂联合方案是一种对卵巢癌具有良好无进展生存期的治疗方案。
